Upadacitinib: Evidence‑Based Recommendations and Safety Considerations

Evidence Base

• International guidelines and global clinical trials that included diverse populations form the basis for upadacitinib recommendations in India, as no India‑specific trial data exist. 1

Ulcerative Colitis – Induction and Maintenance Dosing

• For induction of remission in ulcerative colitis, administer upadacitinib 45 mg orally once daily for 8 weeks. 1
• For maintenance after achieving a clinical response, use upadacitinib 15 mg or 30 mg orally once daily, selecting the dose based on disease severity and patient risk profile. 1
• High‑certainty evidence demonstrates a large benefit of both induction and maintenance regimens in achieving remission, including in patients previously exposed to biologic therapy. 1

Absolute Contraindications

• Active malignancy is an absolute contraindication to upadacitinib therapy. 1
• Patients aged ≥ 50 years with a history of major adverse cardiovascular events or stroke who also have cardiovascular risk factors should not receive upadacitinib. 1

Risk Stratification (European Medicines Agency Guidance)

• The European Medicines Agency advises extreme caution or avoidance of JAK inhibitors, including upadacitinib, in the following high‑risk groups:

• In patients with VTE risk factors, cancer risk, or major cardiovascular risk, the lowest effective maintenance dose should be used (e.g., 15 mg for ulcerative colitis maintenance rather than 30 mg). 1

Safety Monitoring

• Hyperlipidemia is a recognized adverse effect of upadacitinib; routine lipid panel monitoring is recommended. 1

Alternative Therapies for Ulcerative Colitis

Smoking‑Related Risk

• Current or long‑term former smokers have a significantly higher risk of adverse events when treated with upadacitinib. 1

Upadacitinib Dosing Guidelines

Standard Dosing by Indication

• The standard dose of upadacitinib is 15 mg once daily for rheumatoid arthritis, as recommended by the FDA and EMA, with no dose adjustment needed for renal impairment 2, 3
• For atopic dermatitis, the dose is 15 mg or 30 mg once daily, depending on disease severity, with the 30 mg dose demonstrating highest efficacy for reducing EASI scores 4
• For ulcerative colitis, the induction dose is 45 mg once daily for 8 weeks, followed by a maintenance dose of 15 mg or 30 mg once daily after achieving clinical response 5

Dose Adjustments and Contraindications

• No dose adjustment is needed for mild to moderate hepatic impairment, but upadacitinib is contraindicated in severe hepatic impairment (Child-Pugh C) 2, 3
• No dose adjustment is required for any degree of renal impairment, distinguishing upadacitinib from other JAK inhibitors like baricitinib 2, 3

Critical Safety Considerations

• The European Medicines Agency recommends caution when using JAK inhibitors in patients ≥65 years of age, those with cardiovascular risk factors, current or long-term past smokers, and those at increased risk of malignancy 5
• Baseline screening is required for tuberculosis, hepatitis B, hepatitis C, and pregnancy, as well as complete blood count with differential, liver enzymes, renal function, and lipid panel 2, 4

Monitoring Protocol

• Regular monitoring is required for CBC with differential and liver enzymes, lipid panel, and signs of VTE (chest pain, leg swelling, shortness of breath) 6, 4

Drug Interactions

• No significant interactions have been reported with methotrexate when used in combination with upadacitinib 2, 3

Common Pitfalls to Avoid

• The 30 mg dose should not be used in rheumatoid arthritis, as only the 15 mg dose is approved 2, 4, 5
• Cardiovascular risk stratification should not be overlooked, as the ORAL surveillance study with tofacitinib showed increased MACE and malignancy in high-risk RA patients 6, 5, 7